Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.38
Q's Cash to Debt is ranked higher than
54% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. Q: 0.38 )
Q' s 10-Year Cash to Debt Range
Min: 0.23   Max: No Debt
Current: 0.38

Equity to Asset -0.21
Q's Equity to Asset is ranked lower than
55% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. Q: -0.21 )
Q' s 10-Year Equity to Asset Range
Min: -0.54   Max: -0.21
Current: -0.21

-0.54
-0.21
Interest Coverage 5.87
Q's Interest Coverage is ranked higher than
51% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. Q: 5.87 )
Q' s 10-Year Interest Coverage Range
Min: 2.79   Max: 5.87
Current: 5.87

2.79
5.87
F-Score: 8
Z-Score: 3.42
M-Score: -2.55
WACC vs ROIC
2.23%
55.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.81
Q's Operating margin (%) is ranked higher than
85% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. Q: 10.81 )
Q' s 10-Year Operating margin (%) Range
Min: 7.98   Max: 10.81
Current: 10.81

7.98
10.81
Net-margin (%) 6.53
Q's Net-margin (%) is ranked higher than
84% of the 289 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. Q: 6.53 )
Q' s 10-Year Net-margin (%) Range
Min: 3.65   Max: 6.53
Current: 6.53

3.65
6.53
ROA (%) 11.48
Q's ROA (%) is ranked higher than
94% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. Q: 11.48 )
Q' s 10-Year ROA (%) Range
Min: 7.36   Max: 20.82
Current: 11.48

7.36
20.82
ROC (Joel Greenblatt) (%) 303.40
Q's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.49 vs. Q: 303.40 )
Q' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 208.78   Max: 371.69
Current: 303.4

208.78
371.69
» Q's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

Q Guru Trades in Q1 2014

Paul Tudor Jones 17,916 sh (New)
Joel Greenblatt 17,666 sh (+308.56%)
Steven Cohen 30,923 sh (+230.94%)
Jim Simons 451,300 sh (+133.96%)
Ron Baron 327,309 sh (+29.92%)
Vanguard Health Care Fund 4,686,278 sh (+28.88%)
Caxton Associates 5,000 sh (-90.63%)
» More
Q2 2014

Q Guru Trades in Q2 2014

Ron Baron 402,309 sh (+22.91%)
Vanguard Health Care Fund 5,636,278 sh (+20.27%)
Steven Cohen 11,300 sh (unchged)
Caxton Associates Sold Out
Jim Simons 433,100 sh (-4.03%)
Paul Tudor Jones 12,942 sh (-27.76%)
Joel Greenblatt 7,008 sh (-60.33%)
» More
Q3 2014

Q Guru Trades in Q3 2014

Joel Greenblatt 477,607 sh (+6715.17%)
Paul Tudor Jones 24,488 sh (+89.21%)
Ron Baron 402,749 sh (+0.11%)
Vanguard Health Care Fund 5,636,278 sh (unchged)
Steven Cohen Sold Out
Jim Simons 237,400 sh (-45.19%)
» More
Q4 2014

Q Guru Trades in Q4 2014

Steven Cohen 99,500 sh (New)
Ken Fisher 7,700 sh (New)
Jim Simons 574,300 sh (+141.91%)
Joel Greenblatt 747,251 sh (+56.46%)
Ron Baron 427,749 sh (+6.21%)
Vanguard Health Care Fund 5,636,278 sh (unchged)
Paul Tudor Jones 22,811 sh (-6.85%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.30
Q's P/E(ttm) is ranked higher than
92% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. Q: 25.30 )
Q' s 10-Year P/E(ttm) Range
Min: 20.63   Max: 31.56
Current: 25.3

20.63
31.56
Forward P/E 19.69
Q's Forward P/E is ranked higher than
84% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. Q: 19.69 )
N/A
PE(NRI) 25.00
Q's PE(NRI) is ranked higher than
93% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. Q: 25.00 )
Q' s 10-Year PE(NRI) Range
Min: 20.62   Max: 31.48
Current: 25

20.62
31.48
P/S 1.66
Q's P/S is ranked higher than
83% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.43 vs. Q: 1.66 )
Q' s 10-Year P/S Range
Min: 1.02   Max: 1.7
Current: 1.66

1.02
1.7
PFCF 25.40
Q's PFCF is ranked higher than
86% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. Q: 25.40 )
Q' s 10-Year PFCF Range
Min: 18.77   Max: 35.38
Current: 25.4

18.77
35.38
POCF 20.32
Q's POCF is ranked higher than
86% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. Q: 20.32 )
Q' s 10-Year POCF Range
Min: 14.3   Max: 21.73
Current: 20.32

14.3
21.73
EV-to-EBIT 16.55
Q's EV-to-EBIT is ranked higher than
91% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. Q: 16.55 )
Q' s 10-Year EV-to-EBIT Range
Min: 14.8   Max: 18.3
Current: 16.55

14.8
18.3
Current Ratio 1.46
Q's Current Ratio is ranked higher than
56% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. Q: 1.46 )
Q' s 10-Year Current Ratio Range
Min: 1.15   Max: 1.46
Current: 1.46

1.15
1.46
Quick Ratio 1.46
Q's Quick Ratio is ranked higher than
59% of the 295 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. Q: 1.46 )
Q' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.46
Current: 1.46

1.15
1.46
Days Sales Outstanding 29.74
Q's Days Sales Outstanding is ranked higher than
94% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.03 vs. Q: 29.74 )
Q' s 10-Year Days Sales Outstanding Range
Min: 25.13   Max: 29.74
Current: 29.74

25.13
29.74

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.30
Q's Price/Median PS Value is ranked higher than
69% of the 333 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. Q: 1.30 )
Q' s 10-Year Price/Median PS Value Range
Min: 0.89   Max: 1.08
Current: 1.3

0.89
1.08
Earnings Yield (Greenblatt) 6.00
Q's Earnings Yield (Greenblatt) is ranked higher than
89% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. Q: 6.00 )
Q' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.5   Max: 6.8
Current: 6

5.5
6.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:QTS.Germany,
Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. The Company is engaged in providing biopharmaceutical development services and commercial outsourcing services. The Company's services offerings, helps biopharmaceutical customers, as well as customers in the healthcare industry, to make decisions regarding drug development, commercialization and drug therapy choices. The Company offers services through two segments Product Development; and Integrated Healthcare Services. The Product Development segment provides services and expertise that allow biopharmaceutical companies to outsource the clinical development process from first-in-man trials to post-launch monitoring. Its service offering provides the support and functional expertise necessary at each stage of development, as well as the systems and analytical capabilities to help customers improve product development efficiency and effectiveness. It is comprised of clinical solutions and services and consulting. Clinical solutions and services provide services to develop biopharmaceutical products including project management and clinical monitoring functions for conducting multi-site trials; clinical trial support services that improve clinical trial decision-making, such as laboratories, data management, bio-statistical, safety and pharmacovigilance, early clinical development trials and strategic planning and design services. Consulting provides management consulting services based on life science expertise and analytics, as well as regulatory and compliance consulting services. The Integrated Healthcare Services segment provides the healthcare industry with both geographic presence and commercial capabilities. Its customized commercialization services are designed to accelerate the commercial success of biopharmaceutical and other health-related products. It provides services including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as a growing number of healthcare business services for the broader healthcare sector. Its service offerings include commercial services and other healthcare services. The Company faces competition from traditional CROs, the in-house R&D departments of biopharmaceutical companies, universities and teaching hospitals. Its competitors include; Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc., or inVentiv, INC Research, PRA International, United Drug plc, inVentiv, EPS Corporation and CMIC HOLDINGS Co., Ltd in Japan. In the United States, pharmaceutical, biological and medical device products are subject to extensive regulation by the FDA. Its integrated healthcare services are subject to numerous federal and state laws pertaining to promotional activities involving pharmaceutical products and medical devices, such as the FDA's regulati
» More Articles for NYSE:Q

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 
Qwest to Webcast Third Quarter 2009 Earnings Conference Call Sep 03 2009 
Qwest Reports Second Quarter 2009 Results Jul 29 2009 
Qwest Reports Fourth Quarter and Full Year 2008 Results Feb 10 2009 
Qwest Communications Announces Tax Treatment for 2008 Dividends Jan 19 2009 

More From Our Partners
The March Madness 'Sweet 16' of Stocks - Analyst Blog Mar 26 2015 - ZACKS

More From Other Websites
Quest Diagnostics (DGX) Earnings Report: Q1 2015 Conference Call Transcript Apr 24 2015
Quintiles Transnational upgraded by Jefferies Apr 24 2015
Quintiles and Hospital Italiano of Buenos Aires Announce Agreement to Accelerate Clinical... Apr 16 2015
Quintiles wins Best CRO Award at World Vaccine Congress 2015 Apr 09 2015
Quintiles wins Best CRO Award at World Vaccine Congress 2015 Apr 09 2015
Quintiles’ First Quarter 2015 Earnings Call Scheduled for Wednesday, April 29th Apr 02 2015
Quintiles’ First Quarter 2015 Earnings Call Scheduled for Wednesday, April 29th Apr 02 2015
Personalized medicine a factor in Quintiles-Quest JV Mar 31 2015
Quintiles, Quest Create Lab Services Venture Mar 31 2015
Quintiles, Quest Diagnostics Form Lab Services Joint Venture Mar 31 2015
Quintiles, Quest to test lab joint venture for drugmakers Mar 31 2015
Quintiles, Quest to test lab joint venture for drugmakers Mar 31 2015
Quintiles, Quest to combine clinical trial lab operations Mar 31 2015
Quintiles, Quest Diagnostics to form clinical trial labs joint venture Mar 31 2015
Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory... Mar 31 2015
Novella added 90 workers since Quintiles acquired the CRO Mar 27 2015
Forbes Names Quintiles One of America’s Best Employers Mar 25 2015
Quintiles’ Anand Tharmaratnam Honored as ‘Asian Male Executive of the Year’ in BioPharma Asia... Mar 24 2015
Quintiles’ Anand Tharmaratnam Honored as ‘Asian Male Executive of the Year’ in BioPharma Asia... Mar 24 2015
Duke study reveals challenges of clinical trials results Mar 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK